Evotec CEO Jörn Aldag and Exec VP-Business Development Mark Ashton: An Interview with “The Pink Sheet” DAILY (Part 2 of 2)
This article was originally published in The Pink Sheet Daily
Executive Summary
Execs discuss business development going forward, partnerships with other pharmas and biotechs and the company’s involvement in a new program to work more closely with academia in drug discovery.
You may also be interested in...
Evotec's Restructuring Leads To Q1 Improved Revenues and Reduced Losses
German drug discovery service company expects to be profitable by 2012.
Evotec's Restructuring Leads To Q1 Improved Revenues and Reduced Losses
German drug discovery service company expects to be profitable by 2012.
Evotec CEO Jorn Aldag and Exec VP-Business Development Mark Ashton: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)
Execs discuss firm’s pipeline and its acquisition of Bay-area biotech Renovis.